Diligence memo · auto-generated · as of July 2, 2026

Dermata Therapeutics, LLC

Dermata Therapeutics, LLC looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Dermata Therapeutics, LLC operates in Biotechnology, based in San Diego.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Dermata Therapeutics, LLC has raised $16M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.9M on 2016-01-01.

Most recent recorded round closed around 2020-07-17.

Valuation (modeled)modeled

Provath models Dermata Therapeutics, LLC at approximately $106M (range $3.3M–$572M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.59× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 6.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 65% of Biotechnology peers (4293 compared).

Modeled value ranks above 60% of those peers.

Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.